These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29958729)

  • 1. Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in Japan.
    Okada K; Sato Y; Sugiyama D; Sawa Y
    Clin Ther; 2018 Jul; 40(7):1076-1083. PubMed ID: 29958729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status of the regulation and development of cell therapy products in Japan].
    Igarashi Y; Sato Y
    Nihon Yakurigaku Zasshi; 2018; 151(6):254-259. PubMed ID: 29887575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
    Okada K; Miyata T; Sawa Y
    Regen Med; 2017 Mar; 12(2):179-186. PubMed ID: 28244828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
    Fujita Y; Kawamoto A
    Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
    Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
    Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
    Azuma K; Yamanaka S
    Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intellectual Property in the Field of Regenerative Medicine in Japan.
    Asano S; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1823-1827. PubMed ID: 30458929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
    Inokuma Y
    Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japanese Laws and the Current Status of Regenerative Medicine in the Tohoku Region.
    Kamano Y; Terajima N; Chiba Y; Suresh VV; Saito M
    J Contemp Dent Pract; 2023 Feb; 24(2):120-128. PubMed ID: 37272144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Social Framework Surrounding the Development of Regenerative Medicine in Japan.
    Nakazawa E; Takimoto Y; Akabayashi A
    Camb Q Healthc Ethics; 2016 Jul; 25(3):466-71. PubMed ID: 27348830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
    Okada K; Koike K; Sawa Y
    Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
    Takashima K; Morrison M; Minari J
    Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ideal way to design clinical trials and establishment of evidence for human cellular and tissue-based products in Japan.
    Sawa Y
    J Tissue Eng Regen Med; 2019 Jun; 13(6):905-907. PubMed ID: 30938062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japan's challenges of translational regenerative medicine: Act on the safety of regenerative medicine.
    Tobita M; Konomi K; Torashima Y; Kimura K; Taoka M; Kaminota M
    Regen Ther; 2016 Jun; 4():78-81. PubMed ID: 31245489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell research and regenerative medicine in 2014: first year of regenerative medicine in Japan.
    Okano H
    Stem Cells Dev; 2014 Sep; 23(18):2127-8. PubMed ID: 25192239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
    Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.